Inovio Wins Top Prize at Vaccine Congress Forum Print E-mail
By Staff and Wire Reports   
Wednesday, 05 October 2011 06:14
fda calendarInovio Pharmaceuticals, Inc. (Amex:INO) announced on Wednesday that the company’s research to develop a therapeutic synthetic vaccine for cancer won the Edward Jenner Poster Award First Prize at the recent 5th Vaccine and ISV Global Congress.

This prestigious prize recognizes the most promising research at the Congress. Inovio’s poster, entitled “Induction of HPV specific CTLs in human volunteers after DNA immunization," was selected from over 500 abstracts by the scientific organizing committee and an expert panel of judges. The award citation highlighted Inovio's pioneering therapeutic cervical dysplasia/cancer vaccine program and the novel assay for determining vaccine impact.
 
The Vaccine Congress is a forum for a state-of-the-art report on the latest progress in the development of vaccines for infectious and non-infectious diseases. The annual Jenner Award is named after Edward Jenner (1749-1823), who is widely credited as the pioneer of the smallpox vaccine and is often referred to as the “Father of Immunology.”
 
Dr. J. Joseph Kim, president and CEO, said, "We greatly appreciate this recognition of Inovio's leadership and innovation in advancing the development of novel vaccines and analytical methods to assess vaccine effects. Our SynCon® vaccines administered with our proprietary electroporation delivery systems have generated best-in-class immune responses in our Phase I clinical trials for cervical dysplasia and HIV. The demonstration of antigen-specific CTL activity induced by Inovio’s synthetic vaccines delivered by its proprietary CELLECTRA® electroporation system speaks well for our synthetic vaccine platform in general and in particular for our cancer vaccine programs."

A look at the BioMedReports FDA Calendar and Worldwide Regulatory Catalyst Tracker shows several upcoming milestones for Inovio, including a 4Q11 product status update as it relates to preliminary Phase Ib trial results for Pennvax G for HIV. 

Shares of the company recently fell through support at the $.55 level and are currently trading at -67.95 % from their 52-week high of $1.56 and only 16.28 % higher than their 52-week low (a level established during Tuesday's trading session) of $.43. Like many others in the sector, the stock appears oversold at these levels.

Inovio has active therapeutic vaccine programs for HPV 16 and 18 associated cervical dysplasia/cancer (Phase II), chronic and acute myeloid leukemia (Phase II), prostate cancer (pre-clinical), hepatitis C virus (Phase II), and HIV (Phase I).
 
At the Vaccine Congress, Inovio presented data showing the development of a novel flow cytometry-based assay to assess cytolytic T cell (CTL) activity in immunized patients. Blood samples collected from subjects immunized with Inovio’s SynCon® therapeutic HPV 16 and 18 vaccine (VGX-3100) were analyzed by the new assay. Inovio previously announced the results of its Phase I clinical trial demonstrating the induction of strong T-cell immune responses to the vaccine. An important aspect of a therapeutic vaccine is its ability to generate antigen-specific cytolytic CD8+ T cells that can kill infected host cells. Using the new assay, Inovio scientists were able to demonstrate for the first time that the vaccines developed fully functional CTLs capable of killing targets in an antigen-specific manner – a finding that may prove crucial to the success of an effective therapy for HPV-related disease.

Inovio's product categories include: Cancer DNA vaccines, Infectious disease DNA vaccines, Anti-Inflammatory drugs and Animal health. Its Cancer DNA vaccines include - V930 for breast, colorectal, ovarian and lung cancer; VGX(TM) 3100 therapeutic vaccine for cervical cancer; V934/V935 for breast, lung, prostate and other cancers; and PSMA for prostate cancer. Its Infectious disease DNA vaccines include - Pennvax(TM) family of vaccines for Human Immunodeficiency Virus (HIV), ChronVac-C for hepatitis C virus, etc. Its Anti-inflammatory drug includes - VGX(TM) - 1027 for the treatment of inflammatory diseases including rheumatoid arthritis (RA), Type 1 diabetes (T1D), uveitis and colitis.

Inovio owns a majority interest in VGX Animal Health, Inc., which is focused on the development of pharmaceutical products for animal health applications and markets LifeTide(TM) animal growth hormone for swine. The company has collaborations with, VGX Pharmaceuticals, Inc., Vaccine Research Center, University of Pennsylvania, U.S. Department of Defense, Vandalia Research, Inc, Advanced BioScience Laboratories, Inc, The National Cancer Institute, and others.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter